Protocols: CoLucid shares rocket up on positive migraine PhIII; Sage bags a 'breakthrough' on post-partum depression
Shares of Cambridge, MA-based CoLucid Pharmaceuticals $CLCD soared 90% Tuesday morning after the company declared a success for its Phase III study of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.